Skip to content
lsd.com
CompletedN/A

Pharmacogenetics Associated With IV Ketamine

NCT04695405 · Brain and Cognition Discovery Foundation

Closed to entry
Status
Not accepting participants
Not applicable
Phase
85
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from treatment resistant depression. Patients who have received IV ketamine at the clinic are eligible to participate in this study where genetic biomarkers are correlated with response to IV ketamine.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Genetic Biomarkers

    Measured over 1 month

  • Quick Inventory of Depressive Symptomatology Self Report 16-Item

    Measured over Over 1-2 weeks

  • Generalized Anxiety Disorder 7-item

    Measured over Over 1-2 weeks

  • Snaith-Hamilton Pleasure Scale

    Measured over Over 1-2 weeks

  • Sheehan Disability Scale

    Measured over Over 4 initial infusions

  • Clinician Administered Dissociative States Scale

    Measured over Over 1-2 weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Must have received IV ketamine previously to treat Treatment-Resistant Depression 2. Between the ages of 18-65 years old. 3. Clinical diagnosis of MDD 4. Individuals may have had comorbid psychiatric conditions (e.g., anxiety), but the comorbid psychiatric condition cannot be the primary clinical concern. 5. Ability to provide informed consent Exclusion Criteria: 1. Individuals who meet DSM 5 criteria for a substance use and/or alcohol use disorder in the past 3 months. 2. Individuals who are currently experiencing psychotic symptoms as part of an MDE (mood congruent/mood incongruent). 3. Individuals who are unable to consent to the procedure. 4. Individuals who are unable to adhere to the protocol in its totality

Where

1 study site

FacilityCityRegionCountry
Canadian Rapid Treatment Centre of ExcellenceMississaugaOntarioCanada

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT04695405 on ClinicalTrials.gov →

Last updated in the registry 2021-08-18. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

All 3 trials from Brain and Cognition Discovery Foundation →